Zydus Lifesciences recalled Chlorpromazine Hydrochloride Tablets on September 3, 2025. The tablets contain N-Nitroso Desmethyl Chlorpromazine above safe intake levels. Consumers must stop using the product immediately and consult healthcare providers.
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A
The recalled product is Chlorpromazine Hydrochloride Tablets, USP, 50 mg, sold in 100-count bottles. The affected lot numbers are Z306326 and Z401155, with expiration dates of November 30, 2025, and February 28, 2026, respectively.
The product contains N-Nitroso Desmethyl Chlorpromazine above the acceptable intake limit. This chemical is a potential carcinogen, posing serious health risks.
No specific incidents or injuries related to this recall have been reported. The recall was initiated due to CGMP deviations.
Stop using the recalled tablets immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for further guidance.
For more information, visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0635-2025 or contact Zydus Pharmaceuticals.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.